Therapy Administration

Transrectal gene delivery offers direct targeting of prostate cancers

Published in Gene Therapy Weekly, March 28th, 2002

by Sonia Nichols, senior medical writer - Research performed on larger animal models have demonstrated the efficacy of delivering gene therapy for prostate cancer directly to its intended target.

University of Tennessee investigators have reported one of the first studies to examine the practicality and effectiveness of delivering gene therapy to prostate cancer tumors using a transrectal route. According to their report, the method represents a strategic way to direct adenoviruses encoded for therapeutic genes into malignant prostate cells although a minimal level of systemic dissemination can be expected.

The technique makes use of ultrasound to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-03-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry